Enhanced and sustained activation of human B cells by anti-immunoglobulin conjugated to the EBV glycoprotein gp350

European Journal of Immunology

Volumn 30, Issue 3, 2000, Pages 969-973

  Goeckeritz, Bruce E ^a   Lees, Andrew ^a   Vos, Quirijn ^a   Tsokos, George C ^a   Kuhlbusch, Klaus ^a   Mond, James J ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

B lymphocyte; CD21; Cellular activation; Epstein Barr virus; Vaccine development

Indexed keywords

ANTIBODY; CALCIUM ION; COMPLEMENT RECEPTOR; DEXTRAN; GLYCOPROTEIN; GLYCOPROTEIN 350; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ARTICLE; B LYMPHOCYTE ACTIVATION; CALCIUM CELL LEVEL; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CONJUGATION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL;

EID: 0034003234     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200003)30:3<969::AID-IMMU969>3.0.CO;2-A     Document Type: Article

References (24)

1. Fearon, D. T. and Carter, R. H., The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu. Rev. Immunol. 1995. 13: 127-149.
2. Carroll, M. C. and Fischer, M. B., Complement and the immune response. Curr. Opin. Immunol. 1997. 9: 64-69.
3. Bohnsack, J. F. and Cooper, N. R., CR2 ligands modulate human B cell activation. J. Immunol. 1988. 141: 2569-2576.
4. Tolnay, M. and Tsokos, G. C., Complement receptor 2 in the regulation of the immune response. Clin. Immunol. Immunopathol. 1998. 88: 123-132.
5. Müller-Eberhard, H. J., Molecular organization and function of the complement system. Annu. Rev. Biochem. 1988 57: 321-347.
6. Carter, R. H. and Fearon, D. T., Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM. J. Immunol 1989. 143: 1755-1760.
7. Carter, R. H., Spycher, M. O., Ng, Y. C., Hoffman, R. and Fearon, D. T., Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J. Immunol. 1988. 141: 457-463.
8. Mongini, P. K. A., Vilensky, M. A., Highet, P. F. and Inman, J. K., The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J. Immunol. 1997. 159: 3782-3791.
9. Frade, R., Crevon, M. C., Barel, M., Vazquez, A., Krikorian, L., Charriaut, C. and Galanaud, P., Enhancement of human B cell proliferation by an antibody to the C3d receptor, the gp 140 molecule. Eur. J. Immunol. 1985. 15: 73-76.
10. Wilson, B. S., Platt, J. L. and Kay, N. E., Monoclonal antibodies to the 140,000 mol wt glycoprotein of B lymphocyte membranes (CR2 receptor) initiates proliferation of B cells in vitro. Blood 1985. 66: 824-829.
11. Croix, D. A., Ahearn, J. M., Rosengard, A. M., Han, S., Kelso, G., Ma, M. and Carroll, M. C., Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J. Exp. Med. 1996. 183: 1857-1864.
12. Molina, H., Holers, V. H., Li, B., Fang, Y., Mariathasan, S., Goellner, J., Strauss-Schoenberger, J., Karr, R. W. and Chaplin, D. D., Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. USA 1996. 93: 3357-3361.
13. Hebell, T., Ahearn, J. M. and Fearon, D. T., Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 1991. 254: 102-105.
14. Dempsey, P. W., Allison, M. E. D., Akkaraju, S., Goodnow, C. C. and Fearon, D. T., C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996. 271: 348-350.
15. Griffioen, A. W., Rijkers, G. T., Janssens-Korpela, P. and Zegers, B. J., Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2. Infect. Immun. 1991. 59: 1839-1845.
16. Fingeroth, J. D., Weis, J. J., Tedder, T. F., Strominger, J. L., Biro, P. A. and Fearon, D. T., Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. USA 1984. 81: 4510-4514.
17. Nemerow, G. R., Mold, C., Schwend, V. K., Tollefson, V. and Cooper, N. R., Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/ C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J. Virol. 1987. 61: 1416-1420.
18. Tanner, J. E., Alfieri, C., Chatila, T. A. and Diaz-Mitoma, F., Induction of interleukin-6 after stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350 and gp220 J. Virol. 1996. 70: 570-575.
19. Masucci, M. G., Szigeti, R., Ernberg, I., Hu, C. P., Tornsdottir, S., Frade, R. and Klein, E., Activation of B lymphocytes by Epstein-Barr virus/CD2 receptor interaction. Eur. J. Immunol. 1987. 17: 815-820.
20. Tanner, J., Weis, J., Fearon, D., Whang, Y. and Kieff, E., Epstein-barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 1987. 50: 203-213.
21. Rehe, G. T., Katona, I. M., Brunswick, M., Wahl, L. M., June, C. H. and Mond, J. J., Activation of human B lymphocytes by nanogram concentrations of anti-IgM-dextran conjugates. Eur. J. Immunol. 1990. 20: 1837-1842.
22. Yamada, H., June, C. H., Finkelman, F., Brunswick, M., Ring, M. S., Lees, A. and Mond, J. J., Persistent calcium elevation correlates with the induction of surface immunoglobulinmediated B cell DNA synthesis. J. Exp. Med. 1993. 177: 1613-1621.
23. Lees, A., Morris, S. C., Thyphronitis, G., Holmes, J. M., Inman, J. K. and Finkelman, F. D., Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody. J. Immunol. 1990. 145: 3594-3600.
24. Liossis, S. N., Kovacs, B., Dennis, G., Kammer, G. M. and Tsokos, G. C., B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J. Clin. Invest. 1996. 98: 2549-2557.